Hematologic Malignancy
Diffuse Large B-Cell Lymphoma Activated B-Cell Type
CI-CAN-00005108Explore in graph →
Hematologic6 active trials3 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005108Explore in graph →
Clinical trials
9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02112526 |
| Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma |
| completed |
| Phase 1 |
| 21 |
| Acerta Pharma BVINDUSTRY |
| 2 |
| Dec 20, 2024 |
| clinicaltrials |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | terminated | Phase 1 | 2 | ExelixisINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 27, 2026source: clinicaltrials